Stock Events

Stock Events

Galera Therapeutics 

$16.28
23
+$0.00+0% Friday 20:00

Statistics

Day High
0.105
Day Low
0.088
52W High
30
52W Low
0.088
Volume
48,127
Avg. Volume
512
Mkt Cap
1.23B
P/E Ratio
0.14
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Next
-60
-39.72
-19.45
0.83
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
149.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRTX. It's not an investment recommendation.
NVIDIA
5
NVDA
Vanguard S&P 500
5
VOO
3M
5
MMM
Realty Income
4
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen develops therapies in areas overlapping with Galera's focus on cancer supportive care, making them direct competitors in the oncology market.
Merck
MRK
Mkt Cap305.12B
Merck's extensive portfolio in oncology, including treatments that mitigate side effects of cancer therapy, places it in competition with Galera Therapeutics.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad range of oncology treatments and supportive care products that compete with Galera's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb's involvement in developing and marketing cancer supportive care drugs makes it a competitor to Galera Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, with its focus on innovative treatments in oncology, competes in the same space as Galera Therapeutics.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences' oncology and supportive care portfolio competes with Galera's focus on improving cancer treatment outcomes.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a wide range of oncology treatments, including those for side effects of cancer therapy, competing with Galera Therapeutics.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca's commitment to developing cancer therapies and supportive care solutions places it in direct competition with Galera.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly's portfolio in oncology and treatment of cancer side effects competes with Galera Therapeutics' focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries, through its generic and specialty medicines, including in oncology, competes with Galera Therapeutics' specialized treatments.

About

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Show more...
CEO
Dr. John Mel Sorensen M.D.
Employees
3
Country
United States
ISIN
US36338D1081

Listings

OTCM
US
GRTX
OTC Link
US
GRTXD

0 Comments

Share your thoughts

FAQ

What is Galera Therapeutics stock price today?▼
The current price of GRTX is $16.28 USD — it has increased by +0% in the past 24 hours. Watch Galera Therapeutics stock price performance more closely on the chart.
What is Galera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Galera Therapeutics stocks are traded under the ticker GRTX.
What is Galera Therapeutics market cap?▼
Today Galera Therapeutics has the market capitalization of 1.23B
When is the next Galera Therapeutics earnings date?▼
Galera Therapeutics is going to release the next earnings report on August 12, 2026.
What were Galera Therapeutics earnings last quarter?▼
GRTX earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galera Therapeutics revenue for the last year?▼
Galera Therapeutics revenue for the last year amounts to 0 USD.
What is Galera Therapeutics net income for the last year?▼
GRTX net income for the last year is 149.05M USD.
How many employees does Galera Therapeutics have?▼
As of July 24, 2026, the company has 3 employees.
In which sector is Galera Therapeutics located?▼
Galera Therapeutics operates in the Health & Wellness sector.
When did Galera Therapeutics complete a stock split?▼
The last stock split for Galera Therapeutics was on July 13, 2026 with a ratio of 1:200.
Where is Galera Therapeutics headquartered?▼
Galera Therapeutics is headquartered in Malvern, United States.